TickerHumSide-by-side comparison
Biogen vs Merck & Co.
As of Nov 11, 2026, P/E is 109.3x for Biogen vs 147.9x for Merck & Co.; P/S is 3.6x for Biogen vs 5.4x for Merck & Co.; revenue growth is 2.3% for Biogen vs 4.9% for Merck & Co.; net margin is 3.4% for Biogen vs 3.6% for Merck & Co..
What stands out
- Biogen is cheaper on earnings: 109.3x P/E vs 147.9x for Merck & Co..
- Biogen carries less debt relative to equity: 0.39 vs 1.11 for Merck & Co..
Key metrics
| Metric | BIIB | MRK |
|---|---|---|
| Price | $252.57 | $146.45 |
| Market cap | $37.33B | $361.04B |
| P/E | 109.3x (#1) | 147.9x (#2) |
| P/S | 3.6x (#1) | 5.4x (#2) |
| Revenue growth | 2.3% (#2) | 4.9% (#1) |
| Operating margin | — | — |
| Net margin | 3.4% (#2) | 3.6% (#1) |
| Debt / equity | 0.39 (#1) | 1.11 (#2) |
| 1-year return | +56.4% (#2) | +60.1% (#1) |
| Research score | 53/100 (#1) | 50/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Biogen Inc. (BIIB) — Drug Manufacturers—General
- Merck & Co., Inc. (MRK) — Drug Manufacturers—General